These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 14980540

  • 1. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress.
    Marcucci F, Lefoulon F.
    Drug Discov Today; 2004 Mar 01; 9(5):219-28. PubMed ID: 14980540
    [Abstract] [Full Text] [Related]

  • 2. Passive and active drug targeting: drug delivery to tumors as an example.
    Torchilin VP.
    Handb Exp Pharmacol; 2010 Mar 01; (197):3-53. PubMed ID: 20217525
    [Abstract] [Full Text] [Related]

  • 3. Ligand-based targeted therapy for cancer tissue.
    Das M, Mohanty C, Sahoo SK.
    Expert Opin Drug Deliv; 2009 Mar 01; 6(3):285-304. PubMed ID: 19327045
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.
    Greco F, Vicent MJ.
    Adv Drug Deliv Rev; 2009 Nov 12; 61(13):1203-13. PubMed ID: 19699247
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
    Ojima I.
    Acc Chem Res; 2008 Jan 12; 41(1):108-19. PubMed ID: 17663526
    [Abstract] [Full Text] [Related]

  • 9. Does a targeting ligand influence nanoparticle tumor localization or uptake?
    Pirollo KF, Chang EH.
    Trends Biotechnol; 2008 Oct 12; 26(10):552-8. PubMed ID: 18722682
    [Abstract] [Full Text] [Related]

  • 10. Targeted nucleic acid delivery into tumors: new avenues for cancer therapy.
    Wagner E, Kircheis R, Walker GF.
    Biomed Pharmacother; 2004 Apr 12; 58(3):152-61. PubMed ID: 15082337
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug.
    Hamad I, Moghimi SM.
    Expert Opin Drug Deliv; 2008 Feb 12; 5(2):205-19. PubMed ID: 18248319
    [Abstract] [Full Text] [Related]

  • 13. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
    Low PS, Henne WA, Doorneweerd DD.
    Acc Chem Res; 2008 Jan 12; 41(1):120-9. PubMed ID: 17655275
    [Abstract] [Full Text] [Related]

  • 14. Prodrug strategies in anticancer chemotherapy.
    Kratz F, Müller IA, Ryppa C, Warnecke A.
    ChemMedChem; 2008 Jan 12; 3(1):20-53. PubMed ID: 17963208
    [Abstract] [Full Text] [Related]

  • 15. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.
    Sultana S, Khan MR, Kumar M, Kumar S, Ali M.
    J Drug Target; 2013 Feb 12; 21(2):107-25. PubMed ID: 22873288
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger.
    Gopin A, Pessah N, Shamis M, Rader C, Shabat D.
    Angew Chem Int Ed Engl; 2003 Jan 20; 42(3):327-32. PubMed ID: 12548691
    [No Abstract] [Full Text] [Related]

  • 18. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
    Danhier F, Feron O, Préat V.
    J Control Release; 2010 Dec 01; 148(2):135-46. PubMed ID: 20797419
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Polymer-protein and polymer-drug conjugates in cancer therapy.
    Thanou M, Duncan R.
    Curr Opin Investig Drugs; 2003 Jun 01; 4(6):701-9. PubMed ID: 12901229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.